C07D277/66

Compositions and methods for analyzing cysteine

The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.

Compound and dimer complex embodiments for supramolecular sensing

Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.

Compound and dimer complex embodiments for supramolecular sensing

Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.

COMPOSITIONS AND METHODS FOR ANALYZING CYSTEINE
20230160903 · 2023-05-25 ·

The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.

HOST MATERIAL, COMPOSITION, AND ORGANIC ELECTROLUMINESCENT ELEMENT
20230113918 · 2023-04-13 ·

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group. n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

ORGANIC LIGHT-EMITTING DEVICE
20230111485 · 2023-04-13 · ·

Disclosed is a highly efficient organic light-emitting device that uses an anthracene derivative having a characteristic structure as a host compound in a light-emitting layer of the organic light-emitting device and includes a capping layer formed using a compound having a characteristic structure in the organic light-emitting device.

ORGANIC LIGHT-EMITTING DEVICE
20230111485 · 2023-04-13 · ·

Disclosed is a highly efficient organic light-emitting device that uses an anthracene derivative having a characteristic structure as a host compound in a light-emitting layer of the organic light-emitting device and includes a capping layer formed using a compound having a characteristic structure in the organic light-emitting device.

ORGANIC LIGHT EMITTING ELEMENT
20230142329 · 2023-05-11 · ·

Embodiments of the disclosure relate to an organic light emitting element. Specifically, there may be provided an organic light emitting element having high efficiency or long lifespan by including a first electrode, a second electrode, and an organic material layer positioned therebetween wherein the organic material layer includes a specific compound.

ORGANIC LIGHT EMITTING ELEMENT
20230142329 · 2023-05-11 · ·

Embodiments of the disclosure relate to an organic light emitting element. Specifically, there may be provided an organic light emitting element having high efficiency or long lifespan by including a first electrode, a second electrode, and an organic material layer positioned therebetween wherein the organic material layer includes a specific compound.

Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.